MYO

#4230
Myomo Inc. Common Stock
1.3 5 USD
-0.06%
Market Price
Sector: Healthcare
Base: USD
Profit Currency: USD
Daily Range
1.35
1.36
Year Range
0.60
1.89
Daily Change
-5.59%
Monthly Change
-4.93%
6 month change
+66.67%
Year Change
+73.08%
Previous Close
1.4 3
Open
1.3 5
Low
1.3 5
High
1.3 6
Volume
62
Open full chart

Financials

Overview Statement Statistics Documents

2026

Current report, Q3 FY2026
MYOMO, INC. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
MYOMO, INC. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
MYOMO, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
MYOMO, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
MYOMO, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
MYOMO, INC. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
MYOMO, INC. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
MYOMO, INC. current report, Q1 FY2026
8-K

2025

Annual report, FY2025
MYOMO, INC. annual report, FY2025
10-K
Current report, Q4 FY2025
MYOMO, INC. current report, Q4 FY2025
8-K

MYOMO, INC. current report, 18 June 2020

Full document

Business Context and Reporting Period

This Form 8-K Current Report was filed by MYOMO, INC. on June 18, 2020, with the report signed on June 22, 2020. The filing addresses specific corporate events under Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits).

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on operational and personnel changes rather than financial performance data.

Material Changes

  • Executive Status Change: On June 18, 2020, Dr. Brandon Green, the Company's Chief Medical Officer, transitioned from an officer to a contractor/consultant. He will continue to advise on insurance reimbursement efforts.
  • Contract Terms: The new consulting agreement is for an indefinite term. Termination requires 60 days' written notice, with an earliest termination date of September 30, 2020.
  • Operational Resumption: On June 22, 2020, the Company issued a press release (Exhibit 99.1) stating it resumed fitting MyoPro patients and deliveries as states re-opened following COVID-19 shutdowns.

Guidance, Outlook, and Risks

The filing does not contain specific financial guidance or forward-looking projections. However, the resumption of patient fittings and deliveries indicates a recovery in operations following pandemic-related shutdowns. The transition of the Chief Medical Officer to a contractor role may represent a cost-saving measure or a strategic shift in medical oversight.

Investor Verification Checklist

  • Verify the impact of Dr. Green's transition from officer to contractor on the Company's medical strategy and insurance reimbursement efforts.
  • Review the June 22, 2020 press release (Exhibit 99.1) for details on the volume of resumed patient fittings and deliveries.
  • Confirm if the change in executive status affects the Company's compliance with insurance or regulatory requirements.
  • Check subsequent filings for any financial impact related to the operational resumption or the change in employment status.

News